About: Antigen-Sparing and Enhanced Efficacy of Multivalent Vaccines Adjuvanted with Immunopotentiators in Chickens

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antigen-Sparing and Enhanced Efficacy of Multivalent Vaccines Adjuvanted with Immunopotentiators in Chickens Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antigen-Sparing and Enhanced Efficacy of Multivalent Vaccines Adjuvanted with Immunopotentiators in Chickens
Creator	Liu, Xiufan Hou, Jibo Mei, Mei Feng, Lei Lu, Jihu Tang, Yinghua Wu, Peipei Zhang, Xuehua Wu, Hongzhuan Cho, Michael Leo, Oberdan Laan, Der Van, Jan
Source	PMC
abstract	We previously described that immunopotentiators, CVCVA5, increased the efficacy of H5 and H9 subtype avian influenza vaccines in chickens, ducks, and geese. In this study, we further investigated the effects of the CVCVA5 for improving the efficacy of other univalent or multivalent inactivated vaccines. The immune response administrated with half-dose of monovalent vaccine plus CVCVA5 were higher than those of one dose of monovalent vaccine without immunopotentiators as measured by levels of antibodies from serum, tears and bronchoalveolar lavage fluids, and cytokines of IFNγ and IL-4 from serum. Vaccines included the univalent vaccine of Newcastle Disease virus (ND), Egg Drop Syndrome virus (EDS), Infectious Bronchitis virus (IB), and Infectious Bursal Disease virus (IBD). The CVCVA5 also improved the immune response of both ND and IBD vaccines with less dosage. The sterile protective immunity was monitored with one- or a half-dose of adjuvanted ND vaccine or one dose of adjuvanted IBD vaccine, respectively. The improved immune efficacy was observed in a half-dose of adjuvanted bivalent vaccines compared to one dose of vaccines without CVCVA5 as measured by the antibody levels, including bivalent vaccine of ND-H9, ND-IB, and ND-IBD. The CVCVA5 also boosted the immune efficacy of the tetravalent vaccine (ND-IB-EDS-H9). A half-dose of adjuvanted commercial vaccine or 75% antigen-sparing adjuvanted vaccine elicited similar antibody levels to those of one dose non-adjuvanted commercial vaccines. The CVCVA5 improved the effect of a booster vaccination as measured by the antibody levels against H5 or H9 virus antigens, in which chickens primed with the adjuvanted ND-IB vaccines given a booster with H5–H9 bivalent vaccines without CVCVA5 using 5-day intervals. The inflammatory response may contribute to these additional effects by increasing the levels of IFNγ and IL-4 after the injection of the adjuvanted ND-IB vaccines. Results indicated that the CVCVA5 improved the serum and mucosal antibody levels, cytokine levels of the chickens given the univalent vaccine, and also improved serum antibody titers in bivalent and tetravalent vaccines. This has a potential as an improve vaccine.
has issue date	2017-05-26(xsd:dateTime)
bibo:doi	10.3389/fmicb.2017.00927
bibo:pmid	28603519
has license	cc-by
sha1sum (hex)	678116d4f14c2470ef9dbde987d11b2e9b679865
schema:url	https://doi.org/10.3389/fmicb.2017.00927
resource representing a document's title	Antigen-Sparing and Enhanced Efficacy of Multivalent Vaccines Adjuvanted with Immunopotentiators in Chickens
has PubMed Central identifier	PMC5445108
has PubMed identifier	28603519
schema:publication	Front Microbiol
resource representing a document's body	covid:678116d4f14c2470ef9dbde987d11b2e9b679865#body_text
is schema:about of	named entity 'SPARING' named entity 'VACCINES' named entity 'bivalent' named entity 'Syndrome' named entity 'vaccines' named entity 'improved' named entity 'additional' named entity 'improved' named entity 'IBD' named entity 'virus' named entity 'dosage' named entity 'efficacy' named entity 'antibody' named entity 'vaccine' named entity 'bivalent' named entity 'levels' named entity 'IL-4' named entity 'ADJUVANTED' named entity 'MONITORED' named entity 'INCLUDED' named entity 'ADDITIONAL' named entity 'ANTIBODIES' named entity 'CONTRIBUTE ' named entity 'INFLUENZA VACCINES' named entity 'INCLUDING' covid:arg/678116d4f14c2470ef9dbde987d11b2e9b679865 named entity 'IBD' named entity 'GIVEN' named entity 'ANTIGENS' named entity 'FLUIDS' named entity 'INCREASING' named entity 'HIGHER' named entity 'INDICATED' named entity 'PREVIOUSLY' named entity 'POTENTIAL' named entity 'ENHANCED' named entity 'IFN' named entity 'ADJUVANTED' named entity 'EGG DROP SYNDROME VIRUS' named entity 'IMPROVED' named entity 'ELICITED' named entity 'SIMILAR' named entity 'STUDY' named entity 'DAY' named entity 'MEASURED' named entity 'IMPROVING' named entity 'DUCKS' named entity 'EFFICACY' named entity 'GEESE' named entity 'THESE' named entity 'VACCINES' named entity 'EFFICACY' named entity 'NON-' named entity 'CYTOKINES' named entity 'COMPARED' named entity 'BOOSTER' named entity 'INTERVALS' named entity 'AVIAN INFLUENZA' named entity 'INFECTIOUS BURSAL DISEASE VIRUS' named entity 'INFECTIOUS BRONCHITIS VIRUS' named entity 'OBSERVED' named entity 'INJECTION' named entity 'CHICKENS' named entity 'DESCRIBED' named entity 'RESULTS' named entity 'INFLAMMATORY RESPONSE' named entity 'ANTIGEN' named entity 'SUBTYPE' named entity 'IL-4'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software